Reported Earnings • May 09
First quarter 2026 earnings released: EPS: NT$0.077 (vs NT$0.029 in 1Q 2025) First quarter 2026 results: EPS: NT$0.077 (up from NT$0.029 in 1Q 2025). Revenue: NT$82.1m (up 20% from 1Q 2025). Net income: NT$5.55m (up 164% from 1Q 2025). Profit margin: 6.8% (up from 3.1% in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 13
Full year 2025 earnings released: NT$0.96 loss per share (vs NT$0.17 profit in FY 2024) Full year 2025 results: NT$0.96 loss per share (down from NT$0.17 profit in FY 2024). Revenue: NT$309.3m (down 8.4% from FY 2024). Net loss: NT$69.3m (down NT$81.0m from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Mar 06
DaBomb Protein Biotech Corp., Annual General Meeting, May 22, 2026 DaBomb Protein Biotech Corp., Annual General Meeting, May 22, 2026. Location: no,52, kung yeh 3rd rd., an nan district, tainan city Taiwan Reported Earnings • Nov 05
Third quarter 2025 earnings released: NT$0.17 loss per share (vs NT$0.024 loss in 3Q 2024) Third quarter 2025 results: NT$0.17 loss per share (further deteriorated from NT$0.024 loss in 3Q 2024). Revenue: NT$69.0m (up 21% from 3Q 2024). Net loss: NT$12.4m (loss widened NT$10.8m from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Jul 01
Upcoming dividend of NT$0.40 per share Eligible shareholders must have bought the stock before 08 July 2025. Payment date: 30 July 2025. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 2.1%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (5.2%). Reported Earnings • May 14
First quarter 2025 earnings released: EPS: NT$0.03 (vs NT$0.11 in 1Q 2024) First quarter 2025 results: EPS: NT$0.03 (down from NT$0.11 in 1Q 2024). Revenue: NT$68.6m (down 32% from 1Q 2024). Net income: NT$2.10m (down 69% from 1Q 2024). Profit margin: 3.1% (down from 6.8% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Apr 26
DaBomb Protein Biotech Corp. to Report Q1, 2025 Results on May 02, 2025 DaBomb Protein Biotech Corp. announced that they will report Q1, 2025 results on May 02, 2025 Reported Earnings • Mar 19
Full year 2024 earnings released: EPS: NT$0.17 (vs NT$1.07 loss in FY 2023) Full year 2024 results: EPS: NT$0.17 (up from NT$1.07 loss in FY 2023). Revenue: NT$337.8m (down 12% from FY 2023). Net income: NT$11.6m (up NT$68.7m from FY 2023). Profit margin: 3.4% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Announcement • Mar 06
DaBomb Protein Biotech Corp., Annual General Meeting, May 21, 2025 DaBomb Protein Biotech Corp., Annual General Meeting, May 21, 2025, at 09:00 Taipei Standard Time. Location: no,52, kung yeh 3rd rd., an nan district, tainan city Taiwan Reported Earnings • Nov 18
Third quarter 2024 earnings released: NT$0.02 loss per share (vs NT$0.50 loss in 3Q 2023) Third quarter 2024 results: NT$0.02 loss per share (improved from NT$0.50 loss in 3Q 2023). Revenue: NT$57.0m (down 35% from 3Q 2023). Net loss: NT$1.51m (loss narrowed 95% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 11
Second quarter 2024 earnings released: EPS: NT$0.08 (vs NT$0.19 loss in 2Q 2023) Second quarter 2024 results: EPS: NT$0.08 (up from NT$0.19 loss in 2Q 2023). Revenue: NT$98.0m (flat on 2Q 2023). Net income: NT$5.23m (up NT$15.9m from 2Q 2023). Profit margin: 5.3% (up from net loss in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. New Risk • Jun 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 200% Earnings have declined by 56% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Shareholders have been diluted in the past year (9.7% increase in shares outstanding). Market cap is less than US$100m (NT$2.02b market cap, or US$62.4m). Reported Earnings • May 19
First quarter 2024 earnings released: EPS: NT$0.11 (vs NT$0.34 loss in 1Q 2023) First quarter 2024 results: EPS: NT$0.11 (up from NT$0.34 loss in 1Q 2023). Revenue: NT$101.2m (up 1.9% from 1Q 2023). Net income: NT$6.85m (up NT$20.3m from 1Q 2023). Profit margin: 6.8% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 11
DaBomb Protein Corp., Annual General Meeting, Jun 27, 2024 DaBomb Protein Corp., Annual General Meeting, Jun 27, 2024. New Risk • Apr 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$1.70b market cap, or US$53.2m). Reported Earnings • Apr 02
Full year 2023 earnings released: NT$1.07 loss per share (vs NT$1.15 loss in FY 2022) Full year 2023 results: NT$1.07 loss per share. Revenue: NT$384.4m (down 11% from FY 2022). Net loss: NT$57.0m (loss widened 28% from FY 2022). New Risk • Feb 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Dividend per share is over 19x cash flows per share. Earnings have declined by 65% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (NT$1.50b market cap, or US$47.6m). Reported Earnings • Aug 11
Second quarter 2023 earnings released: NT$0.19 loss per share (vs NT$0.39 loss in 2Q 2022) Second quarter 2023 results: NT$0.19 loss per share (improved from NT$0.39 loss in 2Q 2022). Revenue: NT$97.4m (down 16% from 2Q 2022). Net loss: NT$10.7m (loss narrowed 30% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Jul 20
Upcoming dividend of NT$0.67 per share Eligible shareholders must have bought the stock before 27 July 2023. Payment date: 31 August 2023. The company last paid an ordinary dividend in August 2016. The average dividend yield among industry peers is 2.8%. New Risk • Jul 19
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.3% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (2.3% operating cash flow to total debt). Earnings have declined by 69% per year over the past 5 years. Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$1.10b market cap, or US$35.4m). Reported Earnings • Mar 31
Full year 2022 earnings released: NT$1.15 loss per share (vs NT$1.92 loss in FY 2021) Full year 2022 results: NT$1.15 loss per share (improved from NT$1.92 loss in FY 2021). Revenue: NT$433.6m (down 7.9% from FY 2021). Net loss: NT$44.7m (loss narrowed 28% from FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Aug 10
Second quarter 2022 earnings released: NT$0.39 loss per share (vs NT$0.27 loss in 2Q 2021) Second quarter 2022 results: NT$0.39 loss per share (down from NT$0.27 loss in 2Q 2021). Revenue: NT$116.1m (up 7.5% from 2Q 2021). Net loss: NT$15.2m (loss widened 71% from 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance. Reported Earnings • May 16
First quarter 2022 earnings released: NT$0.28 loss per share (vs NT$0.84 loss in 1Q 2021) First quarter 2022 results: NT$0.28 loss per share (up from NT$0.84 loss in 1Q 2021). Revenue: NT$115.4m (down 10% from 1Q 2021). Net loss: NT$10.7m (loss narrowed 61% from 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 120 percentage points per year, which is a significant difference in performance. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Nov 13
Third quarter 2021 earnings released: NT$0.42 loss per share (vs NT$0.26 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: NT$107.1m (down 31% from 3Q 2020). Net loss: NT$13.6m (down 262% from profit in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 102 percentage points per year, which is a significant difference in performance. Upcoming Dividend • Aug 16
Upcoming dividend of NT$0.20 per share Eligible shareholders must have bought the stock before 23 August 2021. Payment date: 30 September 2021. Trailing yield: 1.1%. Lower than top quartile of Taiwanese dividend payers (5.2%). Lower than average of industry peers (3.8%). Reported Earnings • May 17
First quarter 2021 earnings released: NT$0.92 loss per share (vs NT$0.20 loss in 1Q 2020) The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: NT$128.7m (up 19% from 1Q 2020). Net loss: NT$27.1m (loss widened 370% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 20
Full year 2020 earnings released: EPS NT$0.24 (vs NT$0.72 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$605.2m (down 6.4% from FY 2019). Net income: NT$7.19m (down 66% from FY 2019). Profit margin: 1.2% (down from 3.3% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Announcement • Mar 13
DaBomb Protein Corp., Annual General Meeting, Jun 10, 2021 DaBomb Protein Corp., Annual General Meeting, Jun 10, 2021. Is New 90 Day High Low • Mar 11
New 90-day high: NT$23.10 The company is up 13% from its price of NT$20.40 on 11 December 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 3.0% over the same period. Is New 90 Day High Low • Dec 31
New 90-day high: NT$21.25 The company is up 15% from its price of NT$18.50 on 30 September 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 8.0% over the same period. Reported Earnings • Nov 10
Third quarter 2020 earnings released: EPS NT$0.29 The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: NT$155.5m (down 15% from 3Q 2019). Net income: NT$8.42m (up 83% from 3Q 2019). Profit margin: 5.4% (up from 2.5% in 3Q 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Oct 28
New 90-day low: NT$18.30 The company is down 8.0% from its price of NT$19.90 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 4.0% over the same period. 